Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus radiotherapy versus zoledronic acid plus radiotherapy for bone metastases from advanced malignant tumors
ChiCTR-IPR-17010456Phase 4Recruiting
- Sponsor
- DA Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib and zoledronic acid in bone metastases and Nonhematologic neoplasms, sponsored by DA Hospital. Started Jan 2017; status: recruiting.
02
Drugs
Rivoceranibzoledronic acid
03
Conditions
bone metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR-IPR-17010456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010456.